1. Generics Bulletin
  2. >>Content

What’s Next? Five Things To Look Out For In June

 
• By Dean Rudge

Generics Bulletin previews the most noteworthy and anticipated events for June 2025.

What's Next Image
Source: Norstella/Citeline

Today, 1 June, Celltrion’s Stoboclo and Osenvelt (denosumab-bmwo) biosimilars – approved by the FDA in February – are set to follow Sandoz’s late May entry into the US denosumab market.

Under the terms of a settlement reached with Amgen earlier this year that paved the way...

Read the full article – start your free trial today!

Join thousands of industry professionals who rely on Generics Bulletin for daily insights

  • Start your 7-day free trial
  • Explore trusted news, analysis, and insights
  • Access comprehensive global coverage
  • Enjoy instant access – no credit card required
Start Free Trial

Already a subscriber?

More from Content

What’s Next? Five Things To Look Out For In June

 
• By Dean Rudge

Generics Bulletin previews the most noteworthy and anticipated events for June 2025.

More from Generics Bulletin

Replacements Named As Eder Leaves Stada And Medicines For Europe

 
• By Dave Wallace

Stephan Eder has left Stada and stepped down as president of Medicines for Europe, with the company announcing plans for his replacement and the association naming Polpharma CEO Markus Sieger as the association’s new interim president.

Reshaped Xbrane Allies With OneSource For Commercial Biosimilar Manufacturing

 
• By Dean Rudge

Xbrane Biopharma is partnering with India’s OneSource Specialty Pharma to manufacture its biosimilars, including its much-delayed ranibizumab product Ximluci. The move follows a SEK240m funding round and strategic refocus on commercialization after divesting key R&D assets to Alvotech.

Hyloris Secures US Approval For Avenacy-Partnered RTU Tranexamic Acid

 
• By Adam Zamecnik

After signing a deal with Avenacy at the end of last year, Hyloris has now announced the approval of its intravenous formulation of tranexamic acid, which is used as a hemostatic agent.